|
|
|
96TH GENERAL ASSEMBLY
State of Illinois
2009 and 2010 HB0333
Introduced 1/27/2009, by Rep. Jack D. Franks SYNOPSIS AS INTRODUCED: |
|
|
Creates the Prescription Drug Repository Program Act. Requires the Department of Public Health to establish a prescription drug repository program, under which any person may donate a prescription drug or supplies needed to administer a prescription drug for use by an individual who meets eligibility criteria specified by the Department. Sets forth requirements that prescription drugs or supplies must meet in order to be accepted and dispensed under the program. Prohibits the resale of drugs or supplies donated under the program. Provides for civil and criminal immunity for drug and supply manufacturers and individuals. Amends the Pharmacy Practice Act and other Acts to provide that persons engaged in certain activities to the extent permitted or required under the Prescription Drug Repository Program Act are exempt from provisions of those other Acts that might prohibit or otherwise regulate such activity. Amends the Counties Code, the Illinois Food, Drug and Cosmetic Act, and the Illinois Controlled Substances Act. Provides that a coroner may take possession of prescription drugs and controlled substances associated or identified with a person whose death is being investigated.
|
| |
|
|
| FISCAL NOTE ACT MAY APPLY | |
|
|
A BILL FOR
|
|
|
|
|
HB0333 |
|
LRB096 03203 DRJ 13220 b |
|
|
1 |
| AN ACT concerning health.
|
2 |
| Be it enacted by the People of the State of Illinois,
|
3 |
| represented in the General Assembly:
|
4 |
| Section 1. Short title. This Act may be cited as the |
5 |
| Prescription Drug Repository Program Act. |
6 |
| Section 5. Definitions. In this Act: |
7 |
| "Department" means the Department of Public Health. |
8 |
| "Dispense" has the meaning given to that term in the |
9 |
| Pharmacy Practice Act. |
10 |
| "Pharmacist" means an individual licensed to engage in the |
11 |
| practice of pharmacy under the Pharmacy Practice Act. |
12 |
| "Pharmacy" means a pharmacy registered in this State under |
13 |
| the Pharmacy Practice Act. |
14 |
| "Practitioner" means a person licensed in this State to |
15 |
| prescribe and administer drugs or licensed in another state and |
16 |
| recognized by this State as a person authorized to prescribe |
17 |
| and administer drugs. |
18 |
| "Prescription drug" means any prescribed drug that may be |
19 |
| legally dispensed by a pharmacy. "Prescription drug" does not |
20 |
| include drugs for the treatment of cancer that can only be |
21 |
| dispensed to a patient registered with the drug manufacturer in |
22 |
| accordance with federal Food and Drug Administration |
23 |
| requirements. |
|
|
|
HB0333 |
- 2 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| "Program" means the prescription drug repository program |
2 |
| established under this Act. |
3 |
| Section 10. Prescription drug repository program. The |
4 |
| Department shall establish and maintain a prescription drug |
5 |
| repository program, under which any person may donate a |
6 |
| prescription drug or supplies needed to administer a |
7 |
| prescription drug for use by an individual who meets |
8 |
| appropriate eligibility criteria. Donations may be made on the |
9 |
| premises of a pharmacy that elects to participate in the |
10 |
| program and meets appropriate requirements. The pharmacy may |
11 |
| charge an individual who receives a prescription drug or |
12 |
| supplies needed to administer a prescription drug under this |
13 |
| Act a handling fee that may not exceed an appropriate amount. A |
14 |
| pharmacy that receives a donated prescription drug or supplies |
15 |
| needed to administer a prescription drug under this Act may |
16 |
| distribute the prescription drug or supplies to another |
17 |
| eligible pharmacy for use under the program.
|
18 |
| Section 15. Requirements for accepting and dispensing |
19 |
| prescription drugs and supplies. A prescription drug or |
20 |
| supplies needed to administer a prescription drug may be |
21 |
| accepted and dispensed under the program only if all of the |
22 |
| following requirements are met:
|
23 |
| (1) The prescription drug or supplies needed to |
24 |
| administer a prescription drug are in their original, |
|
|
|
HB0333 |
- 3 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| unopened, sealed, and tamper-evident unit-dose packaging |
2 |
| or, if packaged in single-unit doses, the single-unit-dose |
3 |
| packaging is unopened.
|
4 |
| (2) The prescription drug bears an expiration date that |
5 |
| is later than 6 months after the date that the drug was |
6 |
| donated.
|
7 |
| (3) The prescription drug or supplies needed to |
8 |
| administer a prescription drug are not adulterated or |
9 |
| misbranded, as determined by a pharmacist employed by, or |
10 |
| under contract with, the pharmacy where the drug or |
11 |
| supplies are accepted or dispensed. The pharmacist must |
12 |
| inspect the drug or supplies before the drug or supplies |
13 |
| are dispensed.
|
14 |
| (4) The prescription drug or supplies needed to |
15 |
| administer a prescription drug are prescribed by a |
16 |
| practitioner for use by an eligible individual.
|
17 |
| Section 20. Resale of donated drugs or supplies prohibited. |
18 |
| No prescription drug or supplies needed to administer a |
19 |
| prescription drug that are donated for use under this Act may |
20 |
| be resold.
|
21 |
| Section 25. Participation in program not required. Nothing |
22 |
| in this Act requires that a pharmacy or pharmacist participate |
23 |
| in the prescription drug repository program.
|
|
|
|
HB0333 |
- 4 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| Section 30. Immunity. |
2 |
| (a) Unless the manufacturer's conduct is wilful and wanton, |
3 |
| a manufacturer of a drug or supply is not subject to criminal |
4 |
| or civil liability for injury, death, or loss to a person or |
5 |
| property for matters related to the donation, acceptance, or |
6 |
| dispensing of a prescription drug or supply manufactured by the |
7 |
| manufacturer that is donated by any person under this Act.
|
8 |
| (b) Unless the person's conduct is wilful and wanton, a |
9 |
| person is immune from civil liability for injury to or the |
10 |
| death of the individual to whom the prescription drug or supply |
11 |
| is dispensed and may not be found guilty of unprofessional |
12 |
| conduct for his or her acts or omissions related to donating, |
13 |
| accepting, distributing, or dispensing a prescription drug or |
14 |
| supply under this Act. |
15 |
| Section 35. Rules. The Department may adopt rules |
16 |
| establishing standards for the disposal of drugs not accepted |
17 |
| under the program. |
18 |
| Section 90. The Counties Code is amended by changing |
19 |
| Section 3-3013 as follows:
|
20 |
| (55 ILCS 5/3-3013) (from Ch. 34, par. 3-3013)
|
21 |
| Sec. 3-3013. Preliminary investigations; blood and urine |
22 |
| analysis;
summoning jury. Every coroner, whenever, as soon as |
23 |
| he knows or is
informed that the dead body of any person is |
|
|
|
HB0333 |
- 5 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| found, or lying within his
county, whose death is suspected of |
2 |
| being:
|
3 |
| (a) A sudden or violent death, whether apparently |
4 |
| suicidal,
homicidal or accidental, including but not |
5 |
| limited to deaths apparently
caused or contributed to by |
6 |
| thermal, traumatic, chemical, electrical or
radiational |
7 |
| injury, or a complication of any of them, or by drowning or
|
8 |
| suffocation, or as a result of domestic violence as defined |
9 |
| in the Illinois
Domestic
Violence Act of 1986;
|
10 |
| (b) A maternal or fetal death due to abortion, or any |
11 |
| death due to a
sex crime or a crime against nature;
|
12 |
| (c) A death where the circumstances are suspicious, |
13 |
| obscure,
mysterious or otherwise unexplained or where, in |
14 |
| the written opinion of
the attending physician, the cause |
15 |
| of death is not determined;
|
16 |
| (d) A death where addiction to alcohol or to any drug |
17 |
| may have been
a contributory cause; or
|
18 |
| (e) A death where the decedent was not attended by a |
19 |
| licensed
physician;
|
20 |
| shall go to the place where the dead body is, and take charge |
21 |
| of the
same and shall make a preliminary investigation into the |
22 |
| circumstances
of the death. In the case of death without |
23 |
| attendance by a licensed
physician the body may be moved with |
24 |
| the coroner's consent from the
place of death to a mortuary in |
25 |
| the same county. Coroners in their
discretion shall notify such |
26 |
| physician as is designated in accordance
with Section 3-3014 to |
|
|
|
HB0333 |
- 6 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| attempt to ascertain the cause of death, either by
autopsy or |
2 |
| otherwise.
|
3 |
| In connection with an investigation under this Division, |
4 |
| the coroner may take possession of prescription drugs and |
5 |
| controlled substances associated or identified with a person |
6 |
| whose death is being investigated. The coroner shall inventory |
7 |
| the prescription drugs and controlled substances taken during |
8 |
| an investigation. The coroner shall prepare and maintain a |
9 |
| record of the disposition of the prescription drugs and |
10 |
| controlled substances. If the prescription drugs and |
11 |
| controlled substances will be disposed of by the coroner, then |
12 |
| the coroner shall dispose of the prescription drugs and |
13 |
| controlled substances by a safe and environmentally sound |
14 |
| method. For the purpose of this paragraph, "prescription drug" |
15 |
| has the meaning set forth under Section 2.37 of the Illinois |
16 |
| Food, Drug and Cosmetic Act. For the purpose of this paragraph, |
17 |
| "controlled substance" has the meaning set forth under |
18 |
| subsection (f) of Section 102 of the Illinois Controlled |
19 |
| Substances Act. Nothing in this paragraph shall be construed to |
20 |
| authorize or require a coroner to take actions that would |
21 |
| interfere with a criminal investigation or prosecution. |
22 |
| In cases of accidental death involving a motor vehicle in |
23 |
| which the
decedent was (1) the operator or a suspected operator |
24 |
| of a motor
vehicle, or (2) a pedestrian 16 years of age or |
25 |
| older, the coroner shall
require that a blood specimen of at |
26 |
| least 30 cc., and if medically
possible a urine specimen of at |
|
|
|
HB0333 |
- 7 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| least 30 cc. or as much as possible up
to 30 cc., be withdrawn |
2 |
| from the body of the decedent in a timely fashion after
the |
3 |
| accident causing his death, by such physician as has been |
4 |
| designated
in accordance with Section 3-3014, or by the coroner |
5 |
| or deputy coroner or
a qualified person designated by such |
6 |
| physician, coroner, or deputy coroner. If the county
does not |
7 |
| maintain laboratory facilities for making such analysis, the
|
8 |
| blood and urine so drawn shall be sent to the Department of |
9 |
| State Police or any other accredited or State-certified |
10 |
| laboratory
for analysis of the alcohol, carbon monoxide, and |
11 |
| dangerous or
narcotic drug content of such blood and urine |
12 |
| specimens. Each specimen
submitted shall be accompanied by |
13 |
| pertinent information concerning the
decedent upon a form |
14 |
| prescribed by such laboratory. Any
person drawing blood and |
15 |
| urine and any person making any examination of
the blood and |
16 |
| urine under the terms of this Division shall be immune from all
|
17 |
| liability, civil or criminal, that might otherwise be incurred |
18 |
| or
imposed.
|
19 |
| In all other cases coming within the jurisdiction of the |
20 |
| coroner and
referred to in subparagraphs (a) through (e) above, |
21 |
| blood, and whenever
possible, urine samples shall be analyzed |
22 |
| for the presence of alcohol
and other drugs. When the coroner |
23 |
| suspects that drugs may have been
involved in the death, either |
24 |
| directly or indirectly, a toxicological
examination shall be |
25 |
| performed which may include analyses of blood, urine,
bile, |
26 |
| gastric contents and other tissues. When the coroner suspects
a |
|
|
|
HB0333 |
- 8 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| death is due to toxic substances, other than drugs, the coroner |
2 |
| shall
consult with the toxicologist prior to collection of |
3 |
| samples. Information
submitted to the toxicologist shall |
4 |
| include information as to height,
weight, age, sex and race of |
5 |
| the decedent as well as medical history,
medications used by |
6 |
| and the manner of death of decedent.
|
7 |
| When the coroner or medical examiner finds that the cause |
8 |
| of death is due to homicidal means, the coroner or medical |
9 |
| examiner shall cause blood and buccal specimens (tissue may be |
10 |
| submitted if no uncontaminated blood or buccal specimen can be |
11 |
| obtained), whenever possible, to be withdrawn from the body of |
12 |
| the decedent in a timely fashion. Within 45 days after the |
13 |
| collection of the specimens, the coroner or medical examiner |
14 |
| shall deliver those specimens, dried, to the Illinois |
15 |
| Department of State Police, Division of Forensic Services, for |
16 |
| analysis and categorizing into genetic marker groupings to be |
17 |
| maintained by the Illinois Department of State Police in the |
18 |
| State central repository in the same manner, and subject to the |
19 |
| same conditions, as provided in Section 5-4-3 of the Unified |
20 |
| Code of Corrections. The requirements of this paragraph are in |
21 |
| addition to any other findings, specimens, or information that |
22 |
| the coroner or medical examiner is required to provide during |
23 |
| the conduct of a criminal investigation.
|
24 |
| In all counties, in cases of apparent
suicide, homicide, or |
25 |
| accidental death or in other cases, within the
discretion of |
26 |
| the coroner, the coroner may summon 8 persons of lawful age
|
|
|
|
HB0333 |
- 9 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| from those persons drawn for petit jurors in the county. The |
2 |
| summons shall
command these persons to present themselves |
3 |
| personally at such a place and
time as the coroner shall |
4 |
| determine, and may be in any form which the
coroner shall |
5 |
| determine and may incorporate any reasonable form of request
|
6 |
| for acknowledgement which the coroner deems practical and |
7 |
| provides a
reliable proof of service. The summons may be served |
8 |
| by first class mail.
From the 8 persons so summoned, the |
9 |
| coroner shall select 6 to serve as the
jury for the inquest. |
10 |
| Inquests may be continued from time
to time, as the coroner may |
11 |
| deem necessary. The 6 jurors selected in
a given case may view |
12 |
| the body of the deceased.
If at any continuation of an inquest |
13 |
| one or more of the original jurors
shall be unable to continue |
14 |
| to serve, the coroner shall fill the vacancy or
vacancies. A |
15 |
| juror serving pursuant to this paragraph shall receive
|
16 |
| compensation from the county at the same rate as the rate of |
17 |
| compensation
that is paid to petit or grand jurors in the |
18 |
| county. The coroner shall
furnish to each juror without fee at |
19 |
| the time of his discharge a
certificate of the number of days |
20 |
| in attendance at an inquest, and, upon
being presented with |
21 |
| such certificate, the county treasurer shall pay to
the juror |
22 |
| the sum provided for his services.
|
23 |
| In counties which have a jury commission, in cases of |
24 |
| apparent suicide or
homicide or of accidental death, the |
25 |
| coroner may conduct an inquest. The jury commission shall |
26 |
| provide
at least 8 jurors to the coroner, from whom the coroner |
|
|
|
HB0333 |
- 10 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| shall select any 6
to serve as the jury for the inquest. |
2 |
| Inquests may be continued from time
to time as the coroner may |
3 |
| deem necessary. The 6 jurors originally chosen
in a given case |
4 |
| may view the body of the deceased. If at any continuation
of an |
5 |
| inquest one or more of the 6 jurors originally chosen shall be |
6 |
| unable
to continue to serve, the coroner shall fill the vacancy |
7 |
| or vacancies. At
the coroner's discretion, additional jurors to |
8 |
| fill such vacancies shall be
supplied by the jury commission. A |
9 |
| juror serving pursuant to this
paragraph in such county shall |
10 |
| receive compensation from the county at the
same rate as the |
11 |
| rate of compensation that is paid to petit or grand jurors
in |
12 |
| the county.
|
13 |
| In addition, in every case in which domestic violence is |
14 |
| determined to be
a
contributing factor in a death, the coroner |
15 |
| shall report the death to the
Department of State Police.
|
16 |
| All deaths in State institutions and all deaths of wards of |
17 |
| the State in
private care facilities or in programs funded by |
18 |
| the Department of Human
Services under its powers relating to |
19 |
| mental health and developmental
disabilities or alcoholism and |
20 |
| substance
abuse or funded by the Department of Children and |
21 |
| Family Services shall
be reported to the coroner of the county |
22 |
| in which the facility is
located. If the coroner has reason to |
23 |
| believe that an investigation is
needed to determine whether |
24 |
| the death was caused by maltreatment or
negligent care of the |
25 |
| ward of the State, the coroner may conduct a
preliminary |
26 |
| investigation of the circumstances of such death as in cases of
|
|
|
|
HB0333 |
- 11 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| death under circumstances set forth in paragraphs (a) through |
2 |
| (e) of this
Section.
|
3 |
| (Source: P.A. 94-924, eff. 1-1-07; 95-484, eff. 6-1-08 .)
|
4 |
| Section 91. The Pharmacy Practice Act is amended by |
5 |
| changing Section 4 as follows:
|
6 |
| (225 ILCS 85/4) (from Ch. 111, par. 4124)
|
7 |
| (Section scheduled to be repealed on January 1, 2018)
|
8 |
| Sec. 4. Exemptions. Nothing contained in any Section of |
9 |
| this Act shall
apply
to, or in any manner interfere with:
|
10 |
| (a) the lawful practice of any physician licensed to |
11 |
| practice medicine in
all of its branches, dentist, podiatrist,
|
12 |
| veterinarian, or therapeutically or diagnostically certified |
13 |
| optometrist within
the limits of
his or her license, or prevent |
14 |
| him or her from
supplying to his
or her
bona fide patients
such |
15 |
| drugs, medicines, or poisons as may seem to him appropriate;
|
16 |
| (b) the sale of compressed gases;
|
17 |
| (c) the sale of patent or proprietary medicines and |
18 |
| household remedies
when sold in original and unbroken packages |
19 |
| only, if such patent or
proprietary medicines and household |
20 |
| remedies be properly and adequately
labeled as to content and |
21 |
| usage and generally considered and accepted
as harmless and |
22 |
| nonpoisonous when used according to the directions
on the |
23 |
| label, and also do not contain opium or coca leaves, or any
|
24 |
| compound, salt or derivative thereof, or any drug which, |
|
|
|
HB0333 |
- 12 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| according
to the latest editions of the following authoritative |
2 |
| pharmaceutical
treatises and standards, namely, The United |
3 |
| States Pharmacopoeia/National
Formulary (USP/NF), the United |
4 |
| States Dispensatory, and the Accepted
Dental Remedies of the |
5 |
| Council of Dental Therapeutics of the American
Dental |
6 |
| Association or any or either of them, in use on the effective
|
7 |
| date of this Act, or according to the existing provisions of |
8 |
| the Federal
Food, Drug, and Cosmetic Act and Regulations of the |
9 |
| Department of Health
and Human Services, Food and Drug |
10 |
| Administration, promulgated thereunder
now in effect, is |
11 |
| designated, described or considered as a narcotic,
hypnotic, |
12 |
| habit forming, dangerous, or poisonous drug;
|
13 |
| (d) the sale of poultry and livestock remedies in original |
14 |
| and unbroken
packages only, labeled for poultry and livestock |
15 |
| medication;
|
16 |
| (e) the sale of poisonous substances or mixture of |
17 |
| poisonous substances,
in unbroken packages, for nonmedicinal |
18 |
| use in the arts or industries
or for insecticide purposes; |
19 |
| provided, they are properly and adequately
labeled as to |
20 |
| content and such nonmedicinal usage, in conformity
with the |
21 |
| provisions of all applicable federal, state and local laws
and |
22 |
| regulations promulgated thereunder now in effect relating |
23 |
| thereto
and governing the same, and those which are required |
24 |
| under such applicable
laws and regulations to be labeled with |
25 |
| the word "Poison", are also labeled
with the word "Poison" |
26 |
| printed
thereon in prominent type and the name of a readily |
|
|
|
HB0333 |
- 13 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| obtainable antidote
with directions for its administration;
|
2 |
| (f) the delegation of limited prescriptive authority by a |
3 |
| physician
licensed to
practice medicine in all its branches to |
4 |
| a physician assistant
under Section 7.5 of the Physician |
5 |
| Assistant Practice Act of 1987. This
delegated authority under |
6 |
| Section 7.5 of the Physician Assistant Practice Act of 1987 may |
7 |
| but is not required to include prescription of
controlled |
8 |
| substances, as defined in Article II of the
Illinois Controlled |
9 |
| Substances Act, in accordance with written guidelines; and
|
10 |
| (g) the The delegation of prescriptive authority by a |
11 |
| physician
licensed to practice medicine in all its branches to |
12 |
| an advanced practice
nurse in accordance with a written |
13 |
| collaborative
agreement under Section 65-35 of the Nurse |
14 |
| Practice Act. This authority, which is delegated under Section |
15 |
| 65-40 of the Nurse Practice Act, may but is not required to
|
16 |
| include the prescription of Schedule III, IV, or V controlled |
17 |
| substances as
defined
in Article II of the Illinois Controlled |
18 |
| Substances Act ; and .
|
19 |
| (h) the donation or acceptance, or the packaging, |
20 |
| repackaging, or labeling, of prescription drugs to the extent |
21 |
| permitted or required under the Prescription Drug Repository |
22 |
| Program Act.
|
23 |
| (Source: P.A. 95-639, eff. 10-5-07 .)
|
24 |
| Section 92. The Wholesale Drug Distribution Licensing Act |
25 |
| is amended by changing Section 15 as follows:
|
|
|
|
HB0333 |
- 14 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| (225 ILCS 120/15) (from Ch. 111, par. 8301-15)
|
2 |
| (Section scheduled to be repealed on January 1, 2013)
|
3 |
| Sec. 15. Definitions. As used in this Act:
|
4 |
| "Authentication" means the affirmative verification, |
5 |
| before any wholesale distribution of a prescription drug |
6 |
| occurs, that each transaction listed on the pedigree has |
7 |
| occurred. |
8 |
| "Authorized distributor of record" means a wholesale |
9 |
| distributor with whom a manufacturer has established an ongoing |
10 |
| relationship to distribute the manufacturer's prescription |
11 |
| drug. An ongoing relationship is deemed to exist between a |
12 |
| wholesale distributor and a manufacturer when the wholesale |
13 |
| distributor, including any affiliated group of the wholesale |
14 |
| distributor, as defined in Section 1504 of the Internal Revenue |
15 |
| Code, complies with the following: |
16 |
| (1) The wholesale distributor has a written agreement |
17 |
| currently in effect with the manufacturer evidencing the |
18 |
| ongoing relationship; and |
19 |
| (2) The wholesale distributor is listed on the |
20 |
| manufacturer's current list of authorized distributors of |
21 |
| record, which is updated by the manufacturer on no less |
22 |
| than a monthly basis.
|
23 |
| "Blood" means whole blood collected from a single donor and |
24 |
| processed
either for transfusion or further manufacturing.
|
25 |
| "Blood component" means that part of blood separated by |
|
|
|
HB0333 |
- 15 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| physical or
mechanical means.
|
2 |
| "Board" means the State Board of Pharmacy of the Department |
3 |
| of
Professional Regulation.
|
4 |
| "Chain pharmacy warehouse" means a physical location for |
5 |
| prescription drugs that acts as a central warehouse and |
6 |
| performs intracompany sales or transfers of the drugs to a |
7 |
| group of chain or mail order pharmacies that have the same |
8 |
| common ownership and control. Notwithstanding any other |
9 |
| provision of this Act, a chain pharmacy warehouse shall be |
10 |
| considered part of the normal distribution channel. |
11 |
| "Co-licensed partner or product" means an instance where |
12 |
| one or more parties have the right to engage in the |
13 |
| manufacturing or marketing of a prescription drug, consistent |
14 |
| with the FDA's implementation of the Prescription Drug |
15 |
| Marketing Act.
|
16 |
| "Department" means the Department of Financial and
|
17 |
| Professional Regulation.
|
18 |
| "Drop shipment" means the sale of a prescription drug to a |
19 |
| wholesale distributor by the manufacturer of the prescription |
20 |
| drug or that manufacturer's co-licensed product partner, that |
21 |
| manufacturer's third party logistics provider, or that |
22 |
| manufacturer's exclusive distributor or by an authorized |
23 |
| distributor of record that purchased the product directly from |
24 |
| the manufacturer or one of these entities whereby the wholesale |
25 |
| distributor or chain pharmacy warehouse takes title but not |
26 |
| physical possession of such prescription drug and the wholesale |
|
|
|
HB0333 |
- 16 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| distributor invoices the pharmacy, chain pharmacy warehouse, |
2 |
| or other person authorized by law to dispense or administer |
3 |
| such drug to a patient and the pharmacy, chain pharmacy |
4 |
| warehouse, or other authorized person receives delivery of the |
5 |
| prescription drug directly from the manufacturer, that |
6 |
| manufacturer's third party logistics provider, or that |
7 |
| manufacturer's exclusive distributor or from an authorized |
8 |
| distributor of record that purchased the product directly from |
9 |
| the manufacturer or one of these entities.
|
10 |
| "Drug sample" means a unit of a prescription drug that is |
11 |
| not intended to
be sold and is intended to promote the sale of |
12 |
| the drug.
|
13 |
| "Facility" means a facility of a wholesale distributor |
14 |
| where prescription drugs are stored, handled, repackaged, or |
15 |
| offered for sale. |
16 |
| "FDA" means the United States Food and Drug Administration.
|
17 |
| "Manufacturer" means a person licensed or approved by the |
18 |
| FDA to engage in the manufacture of drugs or devices, |
19 |
| consistent with the definition of "manufacturer" set forth in |
20 |
| the FDA's regulations and guidances implementing the |
21 |
| Prescription Drug Marketing Act. "Manufacturer" does not |
22 |
| include anyone who is engaged in the packaging, repackaging, or |
23 |
| labeling of prescription drugs only to the extent required |
24 |
| under the Prescription Drug Repository Program Act. |
25 |
| "Manufacturer's exclusive distributor" means anyone who |
26 |
| contracts with a manufacturer to provide or coordinate |
|
|
|
HB0333 |
- 17 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| warehousing, distribution, or other services on behalf of a |
2 |
| manufacturer and who takes title to that manufacturer's |
3 |
| prescription drug, but who does not have general responsibility |
4 |
| to direct the sale or disposition of the manufacturer's |
5 |
| prescription drug. A manufacturer's exclusive distributor must |
6 |
| be licensed as a wholesale distributor under this Act and, in |
7 |
| order to be considered part of the normal distribution channel, |
8 |
| must also be an authorized distributor of record.
|
9 |
| "Normal distribution channel" means a chain of custody for |
10 |
| a prescription drug that goes, directly or by drop shipment, |
11 |
| from (i) a manufacturer of the prescription drug, (ii) that |
12 |
| manufacturer to that manufacturer's co-licensed partner, (iii) |
13 |
| that manufacturer to that manufacturer's third party logistics |
14 |
| provider, or (iv) that manufacturer to that manufacturer's |
15 |
| exclusive distributor to: |
16 |
| (1) a pharmacy or to other designated persons |
17 |
| authorized by law to dispense or administer the drug to a |
18 |
| patient; |
19 |
| (2) a wholesale distributor to a pharmacy or other |
20 |
| designated persons authorized by law to dispense or |
21 |
| administer the drug to a patient; |
22 |
| (3) a wholesale distributor to a chain pharmacy |
23 |
| warehouse to that chain pharmacy warehouse's intracompany |
24 |
| pharmacy to a patient or other designated persons |
25 |
| authorized by law to dispense or administer the drug to a |
26 |
| patient; |
|
|
|
HB0333 |
- 18 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| (4) a chain pharmacy warehouse to the chain pharmacy |
2 |
| warehouse's intracompany pharmacy or other designated |
3 |
| persons authorized by law to dispense or administer the |
4 |
| drug to the patient; |
5 |
| (5) an authorized distributor of record to one other |
6 |
| authorized distributor of record to an office-based health |
7 |
| care practitioner authorized by law to dispense or |
8 |
| administer the drug to the patient; or |
9 |
| (6) an authorized distributor to a pharmacy or other |
10 |
| persons licensed to dispense or administer the drug. |
11 |
| "Pedigree" means a document or electronic file containing |
12 |
| information that records each wholesale distribution of any |
13 |
| given prescription drug from the point of origin to the final |
14 |
| wholesale distribution point of any given prescription drug.
|
15 |
| "Person" means and includes a natural person, partnership, |
16 |
| association or
corporation.
|
17 |
| "Pharmacy distributor" means any pharmacy licensed in this |
18 |
| State or
hospital pharmacy that is engaged in the delivery or |
19 |
| distribution of
prescription drugs either to any other pharmacy |
20 |
| licensed in this State or
to any other person or entity |
21 |
| including, but not limited to, a wholesale
drug distributor |
22 |
| engaged in the delivery or distribution of prescription
drugs |
23 |
| who is involved in the actual, constructive, or attempted |
24 |
| transfer of
a drug in this State to other than the ultimate |
25 |
| consumer except as
otherwise provided for by law.
|
26 |
| "Prescription drug" means any human drug, including any |
|
|
|
HB0333 |
- 19 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| biological product (except for blood and blood components |
2 |
| intended for transfusion or biological products that are also |
3 |
| medical devices), required by federal law or
regulation to be |
4 |
| dispensed only by a prescription, including finished
dosage |
5 |
| forms and bulk drug substances
subject to Section
503 of the |
6 |
| Federal Food, Drug and Cosmetic Act.
|
7 |
| "Repackage" means repackaging or otherwise changing the |
8 |
| container, wrapper, or labeling to further the distribution of |
9 |
| a prescription drug, excluding that completed by the pharmacist |
10 |
| responsible for dispensing the product to a patient. |
11 |
| "Secretary" means the Secretary of Financial and |
12 |
| Professional Regulation. |
13 |
| "Third party logistics provider" means anyone who |
14 |
| contracts with a prescription drug manufacturer to provide or |
15 |
| coordinate warehousing, distribution, or other services on |
16 |
| behalf of a manufacturer, but does not take title to the |
17 |
| prescription drug or have general responsibility to direct the |
18 |
| prescription drug's sale or disposition. A third party |
19 |
| logistics provider must be licensed as a wholesale distributor |
20 |
| under this Act and, in order to be considered part of the |
21 |
| normal distribution channel, must also be an authorized |
22 |
| distributor of record. |
23 |
| "Wholesale distribution"
means the distribution
of |
24 |
| prescription drugs to persons other than a consumer or patient, |
25 |
| but does
not include any of the following:
|
26 |
| (1)
Intracompany sales of prescription drugs, meaning |
|
|
|
HB0333 |
- 20 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| (i) any transaction or transfer
between any division, |
2 |
| subsidiary, parent, or affiliated or related company
under |
3 |
| the common ownership and control of a corporate entity or |
4 |
| (ii) any transaction or transfer between co-licensees of a |
5 |
| co-licensed product.
|
6 |
| (2) The sale, purchase, distribution, trade, or |
7 |
| transfer of a prescription drug or offer to sell, purchase, |
8 |
| distribute, trade, or transfer a prescription drug for |
9 |
| emergency medical reasons.
|
10 |
| (3) The distribution of prescription drug samples by |
11 |
| manufacturers' representatives. |
12 |
| (4) Drug returns, when conducted by a hospital, health |
13 |
| care entity, or charitable institution in accordance with |
14 |
| federal regulation. |
15 |
| (5) The sale of minimal quantities of prescription |
16 |
| drugs by retail pharmacies to licensed practitioners for |
17 |
| office use. |
18 |
| (6) The sale, purchase, or trade of a drug, an offer to |
19 |
| sell, purchase, or trade a drug, or the dispensing of a |
20 |
| drug pursuant to a prescription. |
21 |
| (7) The sale, transfer, merger, or consolidation of all |
22 |
| or part of the business of a pharmacy or pharmacies from or |
23 |
| with another pharmacy or pharmacies, whether accomplished |
24 |
| as a purchase and sale of stock or business assets. |
25 |
| (8) The sale, purchase, distribution, trade, or |
26 |
| transfer of a prescription drug from one authorized |
|
|
|
HB0333 |
- 21 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| distributor of record to one additional authorized |
2 |
| distributor of record when the manufacturer has stated in |
3 |
| writing to the receiving authorized distributor of record |
4 |
| that the manufacturer is unable to supply the prescription |
5 |
| drug and the supplying authorized distributor of record |
6 |
| states in writing that the prescription drug being supplied |
7 |
| had until that time been exclusively in the normal |
8 |
| distribution channel. |
9 |
| (9) The delivery of or the offer to deliver a |
10 |
| prescription drug by a common carrier solely in the common |
11 |
| carrier's usual course of business of transporting |
12 |
| prescription drugs when the common carrier does not store, |
13 |
| warehouse, or take legal ownership of the prescription |
14 |
| drug. |
15 |
| (10) The sale or transfer from a retail pharmacy, mail |
16 |
| order pharmacy, or chain pharmacy warehouse of expired, |
17 |
| damaged, returned, or recalled prescription drugs to the |
18 |
| original manufacturer, the originating wholesale |
19 |
| distributor, or a third party returns processor.
|
20 |
| (11) The donation of prescription drugs to the extent |
21 |
| permitted under the Prescription Drug Repository Program |
22 |
| Act.
|
23 |
| "Wholesale drug distributor" means anyone
engaged in the
|
24 |
| wholesale distribution of prescription drugs, including |
25 |
| without limitation
manufacturers; repackers; own label |
26 |
| distributors; jobbers; private
label distributors; brokers; |
|
|
|
HB0333 |
- 22 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| warehouses, including manufacturers' and
distributors' |
2 |
| warehouses; manufacturer's exclusive distributors; and |
3 |
| authorized distributors of record; drug wholesalers or |
4 |
| distributors; independent wholesale drug traders; specialty |
5 |
| wholesale distributors; third party logistics providers; and |
6 |
| retail pharmacies that conduct wholesale distribution; and |
7 |
| chain pharmacy warehouses that conduct wholesale distribution. |
8 |
| In order to be considered part of the normal distribution |
9 |
| channel, a wholesale distributor must also be an authorized |
10 |
| distributor of record.
|
11 |
| (Source: P.A. 95-689, eff. 10-29-07.)
|
12 |
| Section 93. The Senior Pharmaceutical Assistance Act is |
13 |
| amended by changing Section 10 as follows:
|
14 |
| (320 ILCS 50/10)
|
15 |
| Sec. 10. Definitions. In this Act:
|
16 |
| "Manufacturer" includes:
|
17 |
| (1) An entity that is engaged in (a) the production, |
18 |
| preparation,
propagation, compounding, conversion, or |
19 |
| processing of prescription drug
products (i) directly or |
20 |
| indirectly by extraction from substances of natural
|
21 |
| origin,
(ii) independently by means of chemical synthesis, |
22 |
| or (iii) by combination of
extraction
and chemical |
23 |
| synthesis; or (b) the packaging, repackaging, labeling or
|
24 |
| re-labeling, or distribution of prescription drug |
|
|
|
HB0333 |
- 23 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| products.
|
2 |
| (2) The entity holding legal title to or possession of |
3 |
| the national
drug code number for the covered prescription |
4 |
| drug.
|
5 |
| The term does not include a wholesale distributor of drugs,
|
6 |
| drugstore chain organization, or retail pharmacy licensed by |
7 |
| the State. The term also does not include anyone who is engaged |
8 |
| in the packaging, repackaging, or labeling of prescription |
9 |
| drugs only to the extent required under the Prescription Drug |
10 |
| Repository Program Act.
|
11 |
| "Prescription drug" means a drug that may be dispensed only |
12 |
| upon
prescription by an authorized prescriber and that is |
13 |
| approved for safety and
effectiveness as a prescription drug |
14 |
| under Section 505 or 507 of the Federal
Food, Drug and Cosmetic |
15 |
| Act.
|
16 |
| "Senior citizen" or "senior" means a person 65 years of age |
17 |
| or
older.
|
18 |
| (Source: P.A. 92-594, eff. 6-27-02.)
|
19 |
| Section 94. The Illinois Food, Drug and Cosmetic Act is |
20 |
| amended by changing Sections 16 and 24 as follows:
|
21 |
| (410 ILCS 620/16) (from Ch. 56 1/2, par. 516)
|
22 |
| Sec. 16. (a) The Director is hereby authorized to |
23 |
| promulgate
regulations exempting from any labeling or |
24 |
| packaging requirement of this
Act drugs and devices which are |
|
|
|
HB0333 |
- 24 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| (i) , in accordance with the practice of the
trade, to be |
2 |
| processed, labeled or repacked in substantial quantities at
|
3 |
| establishments other than those where originally processed or |
4 |
| packaged on
condition that such drugs and devices are not |
5 |
| adulterated or misbranded
under the provisions of this Act upon |
6 |
| removal from such processing,
labeling or repacking |
7 |
| establishment or (ii) packaged, repackaged, or labeled to the |
8 |
| extent required under the Prescription Drug Repository Program |
9 |
| Act .
|
10 |
| (b) Drugs and device labeling or packaging exemptions |
11 |
| adopted under the
Federal Act and supplements thereto or |
12 |
| revisions thereof shall apply to
drugs and devices in Illinois |
13 |
| except insofar as modified or rejected by
regulations |
14 |
| promulgated by the Director.
|
15 |
| (c) A drug intended for use by man which (A) is a |
16 |
| habit-forming drug to
which Section 15 (d) applies; or (B) |
17 |
| because of its toxicity or other
potentiality for harmful |
18 |
| effect or the method of its use or the collateral
measures |
19 |
| necessary to its use is not safe for use except under the
|
20 |
| supervision of a practitioner licensed by law to administer |
21 |
| such drug; or
(C) is limited by an approved application under |
22 |
| Section 505 of the Federal
Act or Section 17 of this Act to use |
23 |
| under the professional supervision of
a practitioner licensed |
24 |
| by law to administer such drug, shall be dispensed
only in |
25 |
| accordance with the provisions of the "Illinois Controlled
|
26 |
| Substances Act". The act of dispensing a drug contrary to the |
|
|
|
HB0333 |
- 25 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| provisions of
this paragraph shall be deemed to be an act which |
2 |
| results in a drug being
misbranded while held for sale.
|
3 |
| (d) Any drug dispensed by filling or refilling a written
or |
4 |
| oral prescription of a practitioner licensed by law to |
5 |
| administer such
drug shall be exempt from the requirements of |
6 |
| Section 15, except
subsections (a), (k) and (l) and clauses (2) |
7 |
| and (3) of subsection (i), and
the packaging requirements of
|
8 |
| subsections (g), (h) and (q), if the drug bears a label |
9 |
| containing the
proprietary name or names, or if there is none, |
10 |
| the established name or
names of the drugs, the dosage and |
11 |
| quantity, unless the prescribing
practitioner, in the interest |
12 |
| of the health of the patient, directs
otherwise in writing, the |
13 |
| name and address of the dispenser, the serial
number and date |
14 |
| of the prescription or of its filling, the name of the
|
15 |
| prescriber and, if stated in the prescription, the name of the |
16 |
| patient, and
the directions for use and the cautionary |
17 |
| statements, if any, contained in
such prescription. This |
18 |
| exemption shall not apply to any drug dispensed in
the course |
19 |
| of the conduct of business of dispensing drugs pursuant to
|
20 |
| diagnosis by mail, or to a drug dispensed in violation of |
21 |
| subsection (a) of
this Section.
|
22 |
| (e) The Director may by regulation remove drugs subject to
|
23 |
| Section 15 (d) and Section 17 from the requirements of |
24 |
| subsection (c) of
this Section when such requirements are not |
25 |
| necessary for the protection of
the public health.
|
26 |
| (f) A drug which is subject to subsection (c) of this |
|
|
|
HB0333 |
- 26 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| Section
shall be deemed to be misbranded if at any time before |
2 |
| dispensing its label
fails to bear the statement "Caution: |
3 |
| Federal Law Prohibits Dispensing Without
Prescription" or |
4 |
| "Caution: State Law Prohibits Dispensing Without
|
5 |
| Prescription". A drug to which subsection (c) of this Section |
6 |
| does not apply
shall be deemed to be misbranded if at any time |
7 |
| prior to dispensing its
label bears the caution statement |
8 |
| quoted in the preceding sentence.
|
9 |
| (g) Nothing in this Section shall be construed to relieve
|
10 |
| any person from any requirement prescribed by or under |
11 |
| authority of law
with respect to controlled substances now |
12 |
| included or which may hereafter
be included within the |
13 |
| classifications of controlled substances cannabis as
defined |
14 |
| in applicable Federal laws relating to controlled substances or
|
15 |
| cannabis or the Cannabis Control Act.
|
16 |
| (Source: P.A. 84-1308.)
|
17 |
| (410 ILCS 620/24) (from Ch. 56 1/2, par. 524)
|
18 |
| Sec. 24. Nothing in this Act shall be construed to limit or |
19 |
| repeal any provisions
of the Illinois Controlled Substances |
20 |
| Act , or the Methamphetamine Control and Community Protection |
21 |
| Act , or Section 3-3013 of the Counties Code .
|
22 |
| (Source: P.A. 94-556, eff. 9-11-05.)
|
23 |
| Section 95. The Illinois Controlled Substances Act is |
24 |
| amended by changing Sections 102 and 103 as follows: |
|
|
|
HB0333 |
- 27 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102) |
2 |
| Sec. 102. Definitions. As used in this Act, unless the |
3 |
| context
otherwise requires:
|
4 |
| (a) "Addict" means any person who habitually uses any drug, |
5 |
| chemical,
substance or dangerous drug other than alcohol so as |
6 |
| to endanger the public
morals, health, safety or welfare or who |
7 |
| is so far addicted to the use of a
dangerous drug or controlled |
8 |
| substance other than alcohol as to have lost
the power of self |
9 |
| control with reference to his addiction.
|
10 |
| (b) "Administer" means the direct application of a |
11 |
| controlled
substance, whether by injection, inhalation, |
12 |
| ingestion, or any other
means, to the body of a patient, |
13 |
| research subject, or animal (as
defined by the Humane |
14 |
| Euthanasia in Animal Shelters Act) by:
|
15 |
| (1) a practitioner (or, in his presence, by his |
16 |
| authorized agent),
|
17 |
| (2) the patient or research subject at the lawful |
18 |
| direction of the
practitioner, or
|
19 |
| (3) a euthanasia technician as defined by the Humane |
20 |
| Euthanasia in
Animal Shelters Act.
|
21 |
| (c) "Agent" means an authorized person who acts on behalf |
22 |
| of or at
the direction of a manufacturer, distributor, or |
23 |
| dispenser. It does not
include a common or contract carrier, |
24 |
| public warehouseman or employee of
the carrier or warehouseman.
|
25 |
| (c-1) "Anabolic Steroids" means any drug or hormonal |
|
|
|
HB0333 |
- 28 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| substance,
chemically and pharmacologically related to |
2 |
| testosterone (other than
estrogens, progestins, and |
3 |
| corticosteroids) that promotes muscle growth,
and includes:
|
4 |
| (i) boldenone,
|
5 |
| (ii) chlorotestosterone,
|
6 |
| (iii) chostebol,
|
7 |
| (iv) dehydrochlormethyltestosterone,
|
8 |
| (v) dihydrotestosterone,
|
9 |
| (vi) drostanolone,
|
10 |
| (vii) ethylestrenol,
|
11 |
| (viii) fluoxymesterone,
|
12 |
| (ix) formebulone,
|
13 |
| (x) mesterolone,
|
14 |
| (xi) methandienone,
|
15 |
| (xii) methandranone,
|
16 |
| (xiii) methandriol,
|
17 |
| (xiv) methandrostenolone,
|
18 |
| (xv) methenolone,
|
19 |
| (xvi) methyltestosterone,
|
20 |
| (xvii) mibolerone,
|
21 |
| (xviii) nandrolone,
|
22 |
| (xix) norethandrolone,
|
23 |
| (xx) oxandrolone,
|
24 |
| (xxi) oxymesterone,
|
25 |
| (xxii) oxymetholone,
|
26 |
| (xxiii) stanolone,
|
|
|
|
HB0333 |
- 29 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| (xxiv) stanozolol,
|
2 |
| (xxv) testolactone,
|
3 |
| (xxvi) testosterone,
|
4 |
| (xxvii) trenbolone, and
|
5 |
| (xxviii) any salt, ester, or isomer of a drug or |
6 |
| substance described
or listed in this paragraph, if |
7 |
| that salt, ester, or isomer promotes muscle
growth.
|
8 |
| Any person who is otherwise lawfully in possession of an |
9 |
| anabolic
steroid, or who otherwise lawfully manufactures, |
10 |
| distributes, dispenses,
delivers, or possesses with intent to |
11 |
| deliver an anabolic steroid, which
anabolic steroid is |
12 |
| expressly intended for and lawfully allowed to be
administered |
13 |
| through implants to livestock or other nonhuman species, and
|
14 |
| which is approved by the Secretary of Health and Human Services |
15 |
| for such
administration, and which the person intends to |
16 |
| administer or have
administered through such implants, shall |
17 |
| not be considered to be in
unauthorized possession or to |
18 |
| unlawfully manufacture, distribute, dispense,
deliver, or |
19 |
| possess with intent to deliver such anabolic steroid for
|
20 |
| purposes of this Act.
|
21 |
| (d) "Administration" means the Drug Enforcement |
22 |
| Administration,
United States Department of Justice, or its |
23 |
| successor agency.
|
24 |
| (e) "Control" means to add a drug or other substance, or |
25 |
| immediate
precursor, to a Schedule under Article II of this Act |
26 |
| whether by
transfer from another Schedule or otherwise.
|
|
|
|
HB0333 |
- 30 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| (f) "Controlled Substance" means a drug, substance, or |
2 |
| immediate
precursor in the Schedules of Article II of this Act.
|
3 |
| (g) "Counterfeit substance" means a controlled substance, |
4 |
| which, or
the container or labeling of which, without |
5 |
| authorization bears the
trademark, trade name, or other |
6 |
| identifying mark, imprint, number or
device, or any likeness |
7 |
| thereof, of a manufacturer, distributor, or
dispenser other |
8 |
| than the person who in fact manufactured, distributed,
or |
9 |
| dispensed the substance.
|
10 |
| (h) "Deliver" or "delivery" means the actual, constructive |
11 |
| or
attempted transfer of possession of a controlled substance, |
12 |
| with or
without consideration, whether or not there is an |
13 |
| agency relationship.
The term does not include the donation of |
14 |
| prescription drugs to the extent permitted under the |
15 |
| Prescription Drug Repository Program Act.
|
16 |
| (i) "Department" means the Illinois Department of Human |
17 |
| Services (as
successor to the Department of Alcoholism and |
18 |
| Substance Abuse) or its successor agency.
|
19 |
| (j) "Department of State Police" means the Department of |
20 |
| State
Police of the State of Illinois or its successor agency.
|
21 |
| (k) "Department of Corrections" means the Department of |
22 |
| Corrections
of the State of Illinois or its successor agency.
|
23 |
| (l) "Department of Professional Regulation" means the |
24 |
| Department
of Professional Regulation of the State of Illinois |
25 |
| or its successor agency.
|
26 |
| (m) "Depressant" or "stimulant substance" means:
|
|
|
|
HB0333 |
- 31 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| (1) a drug which contains any quantity of (i) |
2 |
| barbituric acid or
any of the salts of barbituric acid |
3 |
| which has been designated as habit
forming under section |
4 |
| 502 (d) of the Federal Food, Drug, and Cosmetic
Act (21 |
5 |
| U.S.C. 352 (d)); or
|
6 |
| (2) a drug which contains any quantity of (i) |
7 |
| amphetamine or
methamphetamine and any of their optical |
8 |
| isomers; (ii) any salt of
amphetamine or methamphetamine or |
9 |
| any salt of an optical isomer of
amphetamine; or (iii) any |
10 |
| substance which the Department, after
investigation, has |
11 |
| found to be, and by rule designated as, habit forming
|
12 |
| because of its depressant or stimulant effect on the |
13 |
| central nervous
system; or
|
14 |
| (3) lysergic acid diethylamide; or
|
15 |
| (4) any drug which contains any quantity of a substance |
16 |
| which the
Department, after investigation, has found to |
17 |
| have, and by rule
designated as having, a potential for |
18 |
| abuse because of its depressant or
stimulant effect on the |
19 |
| central nervous system or its hallucinogenic
effect.
|
20 |
| (n) (Blank).
|
21 |
| (o) "Director" means the Director of the Department of |
22 |
| State Police or
the Department of Professional Regulation or |
23 |
| his designated agents.
|
24 |
| (p) "Dispense" means to deliver a controlled substance to |
25 |
| an
ultimate user or research subject by or pursuant to the |
26 |
| lawful order of
a prescriber, including the prescribing, |
|
|
|
HB0333 |
- 32 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| administering, packaging,
labeling, or compounding necessary |
2 |
| to prepare the substance for that
delivery.
|
3 |
| (q) "Dispenser" means a practitioner who dispenses.
|
4 |
| (r) "Distribute" means to deliver, other than by |
5 |
| administering or
dispensing, a controlled substance.
|
6 |
| (s) "Distributor" means a person who distributes.
|
7 |
| (t) "Drug" means (1) substances recognized as drugs in the |
8 |
| official
United States Pharmacopoeia, Official Homeopathic |
9 |
| Pharmacopoeia of the
United States, or official National |
10 |
| Formulary, or any supplement to any
of them; (2) substances |
11 |
| intended for use in diagnosis, cure, mitigation,
treatment, or |
12 |
| prevention of disease in man or animals; (3) substances
(other |
13 |
| than food) intended to affect the structure of any function of
|
14 |
| the body of man or animals and (4) substances intended for use |
15 |
| as a
component of any article specified in clause (1), (2), or |
16 |
| (3) of this
subsection. It does not include devices or their |
17 |
| components, parts, or
accessories.
|
18 |
| (t-5) "Euthanasia agency" means
an entity certified by the |
19 |
| Department of Professional Regulation for the
purpose of animal |
20 |
| euthanasia that holds an animal control facility license or
|
21 |
| animal
shelter license under the Animal Welfare Act. A |
22 |
| euthanasia agency is
authorized to purchase, store, possess, |
23 |
| and utilize Schedule II nonnarcotic and
Schedule III |
24 |
| nonnarcotic drugs for the sole purpose of animal euthanasia.
|
25 |
| (t-10) "Euthanasia drugs" means Schedule II or Schedule III |
26 |
| substances
(nonnarcotic controlled substances) that are used |
|
|
|
HB0333 |
- 33 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| by a euthanasia agency for
the purpose of animal euthanasia.
|
2 |
| (u) "Good faith" means the prescribing or dispensing of a |
3 |
| controlled
substance by a practitioner in the regular course of |
4 |
| professional
treatment to or for any person who is under his |
5 |
| treatment for a
pathology or condition other than that |
6 |
| individual's physical or
psychological dependence upon or |
7 |
| addiction to a controlled substance,
except as provided herein: |
8 |
| and application of the term to a pharmacist
shall mean the |
9 |
| dispensing of a controlled substance pursuant to the
|
10 |
| prescriber's order which in the professional judgment of the |
11 |
| pharmacist
is lawful. The pharmacist shall be guided by |
12 |
| accepted professional
standards including, but not limited to |
13 |
| the following, in making the
judgment:
|
14 |
| (1) lack of consistency of doctor-patient |
15 |
| relationship,
|
16 |
| (2) frequency of prescriptions for same drug by one |
17 |
| prescriber for
large numbers of patients,
|
18 |
| (3) quantities beyond those normally prescribed,
|
19 |
| (4) unusual dosages,
|
20 |
| (5) unusual geographic distances between patient, |
21 |
| pharmacist and
prescriber,
|
22 |
| (6) consistent prescribing of habit-forming drugs.
|
23 |
| (u-1) "Home infusion services" means services provided by a |
24 |
| pharmacy in
compounding solutions for direct administration to |
25 |
| a patient in a private
residence, long-term care facility, or |
26 |
| hospice setting by means of parenteral,
intravenous, |
|
|
|
HB0333 |
- 34 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| intramuscular, subcutaneous, or intraspinal infusion.
|
2 |
| (v) "Immediate precursor" means a substance:
|
3 |
| (1) which the Department has found to be and by rule |
4 |
| designated as
being a principal compound used, or produced |
5 |
| primarily for use, in the
manufacture of a controlled |
6 |
| substance;
|
7 |
| (2) which is an immediate chemical intermediary used or |
8 |
| likely to
be used in the manufacture of such controlled |
9 |
| substance; and
|
10 |
| (3) the control of which is necessary to prevent, |
11 |
| curtail or limit
the manufacture of such controlled |
12 |
| substance.
|
13 |
| (w) "Instructional activities" means the acts of teaching, |
14 |
| educating
or instructing by practitioners using controlled |
15 |
| substances within
educational facilities approved by the State |
16 |
| Board of Education or
its successor agency.
|
17 |
| (x) "Local authorities" means a duly organized State, |
18 |
| County or
Municipal peace unit or police force.
|
19 |
| (y) "Look-alike substance" means a substance, other than a |
20 |
| controlled
substance which (1) by overall dosage unit |
21 |
| appearance, including shape,
color, size, markings or lack |
22 |
| thereof, taste, consistency, or any other
identifying physical |
23 |
| characteristic of the substance, would lead a reasonable
person |
24 |
| to believe that the substance is a controlled substance, or (2) |
25 |
| is
expressly or impliedly represented to be a controlled |
26 |
| substance or is
distributed under circumstances which would |
|
|
|
HB0333 |
- 35 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| lead a reasonable person to
believe that the substance is a |
2 |
| controlled substance. For the purpose of
determining whether |
3 |
| the representations made or the circumstances of the
|
4 |
| distribution would lead a reasonable person to believe the |
5 |
| substance to be
a controlled substance under this clause (2) of |
6 |
| subsection (y), the court or
other authority may consider the |
7 |
| following factors in addition to any other
factor that may be |
8 |
| relevant:
|
9 |
| (a) statements made by the owner or person in control |
10 |
| of the substance
concerning its nature, use or effect;
|
11 |
| (b) statements made to the buyer or recipient that the |
12 |
| substance may
be resold for profit;
|
13 |
| (c) whether the substance is packaged in a manner |
14 |
| normally used for the
illegal distribution of controlled |
15 |
| substances;
|
16 |
| (d) whether the distribution or attempted distribution |
17 |
| included an
exchange of or demand for money or other |
18 |
| property as consideration, and
whether the amount of the |
19 |
| consideration was substantially greater than the
|
20 |
| reasonable retail market value of the substance.
|
21 |
| Clause (1) of this subsection (y) shall not apply to a |
22 |
| noncontrolled
substance in its finished dosage form that was |
23 |
| initially introduced into
commerce prior to the initial |
24 |
| introduction into commerce of a controlled
substance in its |
25 |
| finished dosage form which it may substantially resemble.
|
26 |
| Nothing in this subsection (y) prohibits the dispensing or |
|
|
|
HB0333 |
- 36 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| distributing
of noncontrolled substances by persons authorized |
2 |
| to dispense and
distribute controlled substances under this |
3 |
| Act, provided that such action
would be deemed to be carried |
4 |
| out in good faith under subsection (u) if the
substances |
5 |
| involved were controlled substances.
|
6 |
| Nothing in this subsection (y) or in this Act prohibits the |
7 |
| manufacture,
preparation, propagation, compounding, |
8 |
| processing, packaging, advertising
or distribution of a drug or |
9 |
| drugs by any person registered pursuant to
Section 510 of the |
10 |
| Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
|
11 |
| (y-1) "Mail-order pharmacy" means a pharmacy that is |
12 |
| located in a state
of the United States, other than Illinois, |
13 |
| that delivers, dispenses or
distributes, through the United |
14 |
| States Postal Service or other common
carrier, to Illinois |
15 |
| residents, any substance which requires a prescription.
|
16 |
| (z) "Manufacture" means the production, preparation, |
17 |
| propagation,
compounding, conversion or processing of a |
18 |
| controlled substance other than methamphetamine, either
|
19 |
| directly or indirectly, by extraction from substances of |
20 |
| natural origin,
or independently by means of chemical |
21 |
| synthesis, or by a combination of
extraction and chemical |
22 |
| synthesis, and includes any packaging or
repackaging of the |
23 |
| substance or labeling of its container, except that
this term |
24 |
| does not include:
|
25 |
| (1) by an ultimate user, the preparation or compounding |
26 |
| of a
controlled substance for his own use; or
|
|
|
|
HB0333 |
- 37 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| (2) by a practitioner, or his authorized agent under |
2 |
| his
supervision, the preparation, compounding, packaging, |
3 |
| or labeling of a
controlled substance:
|
4 |
| (a) as an incident to his administering or |
5 |
| dispensing of a
controlled substance in the course of |
6 |
| his professional practice; or
|
7 |
| (b) as an incident to lawful research, teaching or |
8 |
| chemical
analysis and not for sale ; or .
|
9 |
| (3) the packaging, repackaging, or labeling of |
10 |
| prescription drugs only to the extent required under the |
11 |
| Prescription Drug Repository Program Act.
|
12 |
| (z-1) (Blank).
|
13 |
| (aa) "Narcotic drug" means any of the following, whether |
14 |
| produced
directly or indirectly by extraction from substances |
15 |
| of natural origin,
or independently by means of chemical |
16 |
| synthesis, or by a combination of
extraction and chemical |
17 |
| synthesis:
|
18 |
| (1) opium and opiate, and any salt, compound, |
19 |
| derivative, or
preparation of opium or opiate;
|
20 |
| (2) any salt, compound, isomer, derivative, or |
21 |
| preparation thereof
which is chemically equivalent or |
22 |
| identical with any of the substances
referred to in clause |
23 |
| (1), but not including the isoquinoline alkaloids
of opium;
|
24 |
| (3) opium poppy and poppy straw;
|
25 |
| (4) coca leaves and any salts, compound, isomer, salt |
26 |
| of an isomer,
derivative, or preparation of coca leaves |
|
|
|
HB0333 |
- 38 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| including cocaine or ecgonine,
and any salt, compound, |
2 |
| isomer, derivative, or preparation thereof which is
|
3 |
| chemically equivalent or identical with any of these |
4 |
| substances, but not
including decocainized coca leaves or |
5 |
| extractions of coca leaves which do
not contain cocaine or |
6 |
| ecgonine (for the purpose of this paragraph, the
term |
7 |
| "isomer" includes optical, positional and geometric |
8 |
| isomers).
|
9 |
| (bb) "Nurse" means a registered nurse licensed under the
|
10 |
| Nurse Practice Act.
|
11 |
| (cc) (Blank).
|
12 |
| (dd) "Opiate" means any substance having an addiction |
13 |
| forming or
addiction sustaining liability similar to morphine |
14 |
| or being capable of
conversion into a drug having addiction |
15 |
| forming or addiction sustaining
liability.
|
16 |
| (ee) "Opium poppy" means the plant of the species Papaver
|
17 |
| somniferum L., except its seeds.
|
18 |
| (ff) "Parole and Pardon Board" means the Parole and Pardon |
19 |
| Board of
the State of Illinois or its successor agency.
|
20 |
| (gg) "Person" means any individual, corporation, |
21 |
| mail-order pharmacy,
government or governmental subdivision or |
22 |
| agency, business trust, estate,
trust, partnership or |
23 |
| association, or any other entity.
|
24 |
| (hh) "Pharmacist" means any person who holds a license or |
25 |
| certificate of
registration as a registered pharmacist, a local |
26 |
| registered pharmacist
or a registered assistant pharmacist |
|
|
|
HB0333 |
- 39 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| under the Pharmacy Practice Act.
|
2 |
| (ii) "Pharmacy" means any store, ship or other place in |
3 |
| which
pharmacy is authorized to be practiced under the Pharmacy |
4 |
| Practice Act.
|
5 |
| (jj) "Poppy straw" means all parts, except the seeds, of |
6 |
| the opium
poppy, after mowing.
|
7 |
| (kk) "Practitioner" means a physician licensed to practice |
8 |
| medicine in all
its branches, dentist, optometrist, |
9 |
| podiatrist,
veterinarian, scientific investigator, pharmacist, |
10 |
| physician assistant,
advanced practice nurse,
licensed |
11 |
| practical
nurse, registered nurse, hospital, laboratory, or |
12 |
| pharmacy, or other
person licensed, registered, or otherwise |
13 |
| lawfully permitted by the
United States or this State to |
14 |
| distribute, dispense, conduct research
with respect to, |
15 |
| administer or use in teaching or chemical analysis, a
|
16 |
| controlled substance in the course of professional practice or |
17 |
| research.
|
18 |
| (ll) "Pre-printed prescription" means a written |
19 |
| prescription upon which
the designated drug has been indicated |
20 |
| prior to the time of issuance.
|
21 |
| (mm) "Prescriber" means a physician licensed to practice |
22 |
| medicine in all
its branches, dentist, optometrist, podiatrist |
23 |
| or
veterinarian who issues a prescription, a physician |
24 |
| assistant who
issues a
prescription for a Schedule III, IV, or |
25 |
| V controlled substance
in accordance
with Section 303.05 and |
26 |
| the written guidelines required under Section 7.5
of the
|
|
|
|
HB0333 |
- 40 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| Physician Assistant Practice Act of 1987, or an advanced |
2 |
| practice
nurse with prescriptive authority delegated under |
3 |
| Section 65-40 of the Nurse Practice Act and in accordance with |
4 |
| Section 303.05
and a written
collaborative agreement under |
5 |
| Section 65-35 of the Nurse Practice Act.
|
6 |
| (nn) "Prescription" means a lawful written, facsimile, or |
7 |
| verbal order
of
a physician licensed to practice medicine in |
8 |
| all its branches,
dentist, podiatrist or veterinarian for any |
9 |
| controlled
substance, of an optometrist for a Schedule III, IV, |
10 |
| or V controlled substance in accordance with Section 15.1 of |
11 |
| the Illinois Optometric Practice Act of 1987, of a physician |
12 |
| assistant for a Schedule III, IV, or V
controlled substance
in |
13 |
| accordance with Section 303.05 and the written guidelines |
14 |
| required under
Section 7.5 of the
Physician Assistant Practice |
15 |
| Act of 1987, or of an advanced practice
nurse with prescriptive |
16 |
| authority delegated under Section 65-40 of the Nurse Practice |
17 |
| Act who issues a prescription for a Schedule III, IV, or V
|
18 |
| controlled substance in accordance
with
Section 303.05 and a |
19 |
| written collaborative agreement under Section 65-35 of the |
20 |
| Nurse Practice Act.
|
21 |
| (oo) "Production" or "produce" means manufacture, |
22 |
| planting,
cultivating, growing, or harvesting of a controlled |
23 |
| substance other than methamphetamine.
|
24 |
| (pp) "Registrant" means every person who is required to |
25 |
| register
under Section 302 of this Act.
|
26 |
| (qq) "Registry number" means the number assigned to each |
|
|
|
HB0333 |
- 41 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| person
authorized to handle controlled substances under the |
2 |
| laws of the United
States and of this State.
|
3 |
| (rr) "State" includes the State of Illinois and any state, |
4 |
| district,
commonwealth, territory, insular possession thereof, |
5 |
| and any area
subject to the legal authority of the United |
6 |
| States of America.
|
7 |
| (ss) "Ultimate user" means a person who lawfully possesses |
8 |
| a
controlled substance for his own use or for the use of a |
9 |
| member of his
household or for administering to an animal owned |
10 |
| by him or by a member
of his household.
|
11 |
| (Source: P.A. 94-556, eff. 9-11-05; 95-242, eff. 1-1-08; |
12 |
| 95-639, eff. 10-5-07; 95-689, eff. 10-29-07; 95-876, eff. |
13 |
| 8-21-08.)
|
14 |
| (720 ILCS 570/103) (from Ch. 56 1/2, par. 1103)
|
15 |
| Sec. 103. Scope of Act. Nothing in this Act limits the |
16 |
| lawful authority
granted by the
Medical Practice Act of 1987, |
17 |
| the Nurse Practice
Act, the Illinois Optometric Practice Act of |
18 |
| 1987, or
the Pharmacy Practice Act , or Section 3-3013 of the |
19 |
| Counties Code .
|
20 |
| (Source: P.A. 95-242, eff. 1-1-08; 95-639, eff. 10-5-07; |
21 |
| 95-689, eff. 10-29-07; 95-876, eff. 8-21-08.)
|
22 |
| Section 96. The Cannabis and Controlled Substances Tort |
23 |
| Claims Act is amended by changing Section 3 as follows:
|
|
|
|
HB0333 |
- 42 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| (740 ILCS 20/3) (from Ch. 70, par. 903)
|
2 |
| Sec. 3. Definitions. As used in this Act, unless the |
3 |
| context otherwise
requires:
|
4 |
| "Cannabis" includes marihuana, hashish, and other |
5 |
| substances that
are identified as including any parts of the |
6 |
| plant Cannabis Sativa, whether
growing or not, the seeds of |
7 |
| that plant, the resin extracted from any part of
that plant, |
8 |
| and any compound, manufacture, salt, derivative, mixture, or
|
9 |
| preparation of that plant, its seeds, or resin, including
|
10 |
| tetrahydrocannabinol (THC) and all other cannabinol |
11 |
| derivatives, including
its naturally occurring or |
12 |
| synthetically produced ingredients, whether
produced directly |
13 |
| or indirectly by extraction, independently by means of
chemical |
14 |
| synthesis, or by a combination of extraction and chemical
|
15 |
| synthesis. "Cannabis" does not include the mature stalks of |
16 |
| that plant, fiber
produced from those stalks, oil or cake made |
17 |
| from the seeds of that plant,
any other compound, manufacture, |
18 |
| salt, derivative, mixture, or preparation
of mature stalks |
19 |
| (except the extracted resin), fiber, oil
or cake, or the |
20 |
| sterilized seeds of that plant that are incapable of
|
21 |
| germination.
|
22 |
| "Controlled substance" means a drug, substance, or |
23 |
| immediate precursor in
the Schedules of Article II of the |
24 |
| Illinois Controlled Substances Act.
|
25 |
| "Counterfeit substance" means a controlled substance or |
26 |
| the container or
labeling of a controlled substance that, |
|
|
|
HB0333 |
- 43 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| without authorization, bears the
trademark, trade name, or |
2 |
| other identifying mark, imprint, number, device,
or any |
3 |
| likeness thereof of a manufacturer, distributor, or dispenser |
4 |
| other
than the person who in fact manufactured, distributed, or |
5 |
| dispensed the
substance.
|
6 |
| "Deliver" or "delivery" means the actual, constructive, or |
7 |
| attempted
transfer of possession of a controlled substance or |
8 |
| cannabis, with or
without consideration, whether or not there |
9 |
| is an agency relationship. The term does not include the |
10 |
| donation of prescription drugs to the extent permitted under |
11 |
| the Prescription Drug Repository Program Act.
|
12 |
| "Manufacture" means the production, preparation, |
13 |
| propagation,
compounding, conversion, or processing of a |
14 |
| controlled substance, either
directly or indirectly, by |
15 |
| extraction from substances of natural origin,
independently by |
16 |
| means of chemical synthesis, or by a combination of
extraction |
17 |
| and chemical synthesis, and includes any packaging or
|
18 |
| repackaging of the substance or labeling of its container, |
19 |
| except that the
term does not include:
|
20 |
| (1) by an ultimate user, the preparation or compounding |
21 |
| of a
controlled substance for his own use;
|
22 |
| (2) by a practitioner or his authorized agent under his |
23 |
| supervision,
the preparation, compounding, packaging, or |
24 |
| labeling of a controlled substance : ;
|
25 |
| (A) as an incident to his administering or |
26 |
| dispensing of a controlled
substance in the course of |
|
|
|
HB0333 |
- 44 - |
LRB096 03203 DRJ 13220 b |
|
|
1 |
| his professional practice; or
|
2 |
| (B) as an incident to lawful research, teaching or |
3 |
| chemical analysis
and not for sale; or
|
4 |
| (3) the preparation, compounding, packaging, or |
5 |
| labeling of cannabis
as an incident to lawful research, |
6 |
| teaching, or chemical analysis and not
for sale ; or .
|
7 |
| (4) the packaging, repackaging, or labeling of |
8 |
| prescription drugs only to the extent required under the |
9 |
| Prescription Drug Repository Program Act.
|
10 |
| "Owner" means a person who has possession of or any |
11 |
| interest
whatsoever in the property involved.
|
12 |
| "Person" means an individual, a corporation, a government,
|
13 |
| a governmental subdivision or agency, a business trust, an |
14 |
| estate, a trust,
a partnership or association, or any other |
15 |
| entity.
|
16 |
| "Production" means planting, cultivating, tending, or |
17 |
| harvesting.
|
18 |
| "Property" means real property, including things growing |
19 |
| on,
affixed to, and found in land, and tangible or intangible |
20 |
| personal
property, including rights, services, privileges, |
21 |
| interests, claims,
and securities.
|
22 |
| (Source: P.A. 87-544; revised 10-23-08.)
|
|
|
|
HB0333 |
- 45 - |
LRB096 03203 DRJ 13220 b |
|
| 1 |
|
INDEX
| 2 |
|
Statutes amended in order of appearance
|
| 3 |
| New Act |
|
| 4 |
| 55 ILCS 5/3-3013 |
from Ch. 34, par. 3-3013 |
| 5 |
| 225 ILCS 85/4 |
from Ch. 111, par. 4124 |
| 6 |
| 225 ILCS 120/15 |
from Ch. 111, par. 8301-15 |
| 7 |
| 320 ILCS 50/10 |
|
| 8 |
| 410 ILCS 620/16 |
from Ch. 56 1/2, par. 516 |
| 9 |
| 410 ILCS 620/24 |
from Ch. 56 1/2, par. 524 |
| 10 |
| 720 ILCS 570/102 |
from Ch. 56 1/2, par. 1102 |
| 11 |
| 720 ILCS 570/103 |
from Ch. 56 1/2, par. 1103 |
| 12 |
| 740 ILCS 20/3 |
from Ch. 70, par. 903 |
|
|